ACTR T Cell Product

BIOLOGICAL2 trials

Sponsors

Cogent Biosciences, Inc.

Conditions

B Cell LymphomasHER-2 Protein OverexpressionMultiple MyelomaSolid Tumor

Phase 1

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

TerminatedNCT03680560

Cogent Biosciences, Inc.HER-2 Protein Overexpression, Solid Tumor

Start: 2019-03-13End: 2020-03-12Updated: 2020-03-31

Unknown Phase

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

TerminatedNCT02840110

Cogent Biosciences, Inc.B Cell Lymphomas, HER-2 Protein Overexpression, Multiple Myeloma +1

Start: 2016-10-31End: 2021-02-23Updated: 2021-10-11

Related Papers

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

2021-02-156 citations

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma

Blood2019-11-132 citations